Microsoft tanks AI power stocks, plus Eli Lilly expands manufacturing (again)

Microsoft's announcement of a novel in-chip microfluidics cooling system for AI chips, claiming superior efficiency, triggered an initial, though partially recovered, sell-off in AI data center power stocks like GE Vernova, reflecting market uncertainty regarding its immediate impact and scalability. Concurrently, Eli Lilly committed $6.5 billion to a new Houston manufacturing facility to scale production of its oral GLP-1 obesity drug, orforglipron, signaling aggressive expansion ahead of its anticipated 2025 launch. These sector-specific movements occurred as broader markets saw a slight dip, with Federal Reserve Chair Powell's recent remarks leaving expectations for October and December rate cuts unchanged.

Analysis

Sector-specific news drove market activity, overshadowing a stable macroeconomic outlook where Federal Reserve commentary left rate cut expectations for October and December unchanged. Eli Lilly (LLY) signaled aggressive expansion in the highly competitive obesity drug market by announcing a new $6.5 billion manufacturing facility in Texas, its second major capital commitment in two weeks, dedicated to scaling its oral GLP-1 candidate, orforglipron, ahead of a planned FDA filing and potential 2025 launch. In the technology sector, Microsoft (MSFT) unveiled a proprietary in-chip microfluidics cooling system, claimed to be significantly more effective than existing methods. This news triggered an immediate, though partially reversed, sell-off in AI data center power and cooling providers like GE Vernova (GEV), Eaton (ETN), and Vertiv (VRT). However, the market's reaction is viewed as a knee-jerk response, as significant questions remain regarding the new technology's scalability and its near-term impact on the incumbents' established backlogs. Looking ahead, the market awaits Micron's (MU) earnings, which will provide a critical read-through on the health of data center, PC, and smartphone end-markets.

Key Decisions for Investors

• Eli Lilly's $11.5 billion in recent manufacturing commitments for its GLP-1 pipeline significantly de-risks future production constraints, strengthening the long-term thesis for investors confident in the oral drug orforglipron's successful commercialization.
• The sell-off in data center cooling stocks like GEV, ETN, and VRT may represent a tactical opportunity, as the market could be overstating the immediate threat from Microsoft's new technology given unresolved questions around its scalability and timeline.
• Investors with technology sector exposure should closely monitor Micron's upcoming earnings report, as its results and guidance will serve as a key barometer for end-market demand and influence sentiment across the semiconductor ecosystem.